+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Prolia"

Denosumab Market Report 2025 - Product Thumbnail Image

Denosumab Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Osteoporosis - Pipeline Insight, 2024 - Product Thumbnail Image

Osteoporosis - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 80 Pages
  • Global
From
Postmenopausal Osteoporosis - Pipeline Insight, 2025 - Product Thumbnail Image

Postmenopausal Osteoporosis - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 60 Pages
  • Global
From
Osteoporosis: Seven-Market Drug Forecast and Market Analysis - Product Thumbnail Image

Osteoporosis: Seven-Market Drug Forecast and Market Analysis

  • Report
  • June 2024
  • 105 Pages
  • Global
From
From
From
From
Disease Analysis: Osteoporosis - Product Thumbnail Image

Disease Analysis: Osteoporosis

  • Report
  • March 2021
  • 48 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Prolia is a prescription drug used to treat osteoporosis in postmenopausal women. It is a monoclonal antibody that works by inhibiting the activity of a protein called RANKL, which is involved in the breakdown of bones. Prolia is part of a class of drugs known as Endocrine and Metabolic Disorders Drugs, which are used to treat a variety of conditions related to hormones and metabolism. These drugs are used to treat conditions such as diabetes, thyroid disorders, and obesity. Prolia is approved by the US Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. It is available in both injectable and oral forms. The drug is typically administered once every six months. Common side effects of Prolia include joint pain, muscle pain, and fatigue. Companies in the Prolia market include Amgen, Inc., Eli Lilly and Company, and Merck & Co., Inc. Show Less Read more